PE20142338A1 - Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf - Google Patents

Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf

Info

Publication number
PE20142338A1
PE20142338A1 PE2014001381A PE2014001381A PE20142338A1 PE 20142338 A1 PE20142338 A1 PE 20142338A1 PE 2014001381 A PE2014001381 A PE 2014001381A PE 2014001381 A PE2014001381 A PE 2014001381A PE 20142338 A1 PE20142338 A1 PE 20142338A1
Authority
PE
Peru
Prior art keywords
pyrid
phenyl
useful
raf kinase
amino
Prior art date
Application number
PE2014001381A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael D Kaufman
Phenil J Patel
Craig Wolfangel
Original Assignee
Deciphera Pharmaceuticals Llc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deciphera Pharmaceuticals Llc, Lilly Co Eli filed Critical Deciphera Pharmaceuticals Llc
Publication of PE20142338A1 publication Critical patent/PE20142338A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PE2014001381A 2012-03-07 2013-03-05 Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf PE20142338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
PE20142338A1 true PE20142338A1 (es) 2015-01-10

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001381A PE20142338A1 (es) 2012-03-07 2013-03-05 Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf

Country Status (39)

Country Link
US (2) US8741911B2 (OSRAM)
EP (1) EP2850082B1 (OSRAM)
JP (1) JP2015509536A (OSRAM)
KR (1) KR20140129087A (OSRAM)
CN (1) CN104302646B (OSRAM)
AP (1) AP2014007899A0 (OSRAM)
AR (1) AR090151A1 (OSRAM)
AU (1) AU2013230146B2 (OSRAM)
BR (1) BR112014018528A8 (OSRAM)
CA (1) CA2863673A1 (OSRAM)
CL (1) CL2014002220A1 (OSRAM)
CO (1) CO7010837A2 (OSRAM)
CR (1) CR20140378A (OSRAM)
CY (1) CY1117846T1 (OSRAM)
DK (1) DK2850082T3 (OSRAM)
DO (1) DOP2014000200A (OSRAM)
EA (1) EA024824B1 (OSRAM)
EC (1) ECSP14017584A (OSRAM)
ES (1) ES2584387T3 (OSRAM)
HK (1) HK1202541A1 (OSRAM)
HR (1) HRP20160654T1 (OSRAM)
HU (1) HUE028095T2 (OSRAM)
IL (1) IL234052A (OSRAM)
IN (1) IN2014MN01575A (OSRAM)
LT (1) LT2850082T (OSRAM)
MA (1) MA37316B1 (OSRAM)
ME (1) ME02423B (OSRAM)
MX (1) MX2014010701A (OSRAM)
NZ (1) NZ627454A (OSRAM)
PE (1) PE20142338A1 (OSRAM)
PH (1) PH12014501986A1 (OSRAM)
PT (1) PT2850082T (OSRAM)
RS (1) RS54840B1 (OSRAM)
SG (1) SG11201404969YA (OSRAM)
SI (1) SI2850082T1 (OSRAM)
TN (1) TN2014000375A1 (OSRAM)
TW (1) TW201348233A (OSRAM)
UA (1) UA112340C2 (OSRAM)
WO (2) WO2013134252A1 (OSRAM)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
MX2018015353A (es) * 2016-06-10 2019-09-09 Novartis Ag Usos terapeuticos de un inhibidor de c-raf.
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
EP3615083A4 (en) * 2017-04-28 2021-05-19 Zamboni Chem Solutions Inc. RAF DEGRADATION CONJUGATES
MX2020006438A (es) 2017-12-21 2020-09-17 Boehringer Ingelheim Int Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
EP3849536A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
SMT202500389T1 (it) 2018-12-28 2025-11-10 Deciphera Pharmaceuticals Llc Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
SMT202400003T1 (it) 2019-02-06 2024-03-13 Lilly Co Eli Derivati di 1-((2-(2,2,2-trifluoroetossi)piridin-4-il)metil)urea come potenziatori di kcnq
CN113795307A (zh) * 2019-02-18 2021-12-14 基因泰克公司 吡啶并嘧啶基化合物及其使用方法
AU2020268814A1 (en) 2019-05-03 2021-12-16 Kinnate Biopharma Inc. Inhibitors of RAF kinases
EP4295846A3 (en) 2019-05-10 2024-02-28 Deciphera Pharmaceuticals, LLC Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20220597A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
AU2020371727A1 (en) 2019-10-24 2022-05-26 Pierre Fabre Medicament Inhibitors of RAF kinases
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
AU2021285032A1 (en) 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体
AU2021381949A1 (en) 2020-11-18 2023-06-15 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
AR124449A1 (es) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc Inhibidores de sos1 y usos de los mismos
AU2022261117A1 (en) 2021-04-23 2023-11-23 Pierre Fabre Medicament Treatment of cancer with a raf inhibitor
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
CN118613485A (zh) 2021-12-01 2024-09-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
MX2024006681A (es) 2021-12-01 2024-08-26 Boehringer Ingelheim Int Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer.
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
CN118574835A (zh) 2021-12-01 2024-08-30 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
EP4441054A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4444429A1 (en) 2021-12-09 2024-10-16 Deciphera Pharmaceuticals, LLC Raf kinase inhibitors and methods of use thereof
WO2023108103A1 (en) 2021-12-09 2023-06-15 Deciphera Pharmaceuticals, Llc Raf kinase inhibitors and methods of use thereof
EP4452975A1 (en) 2021-12-23 2024-10-30 Boehringer Ingelheim International GmbH 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US20240174641A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
KR20250093392A (ko) 2022-10-26 2025-06-24 베링거 인겔하임 인터내셔날 게엠베하 Sting을 활성화시킬 수 있는 헤테로사이클릭 화합물
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025122952A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US20250313560A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
EP1566379A4 (en) * 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
UY33221A (es) * 2010-02-09 2011-09-30 Univ California MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
IL234052A (en) 2016-05-31
UA112340C2 (uk) 2016-08-25
MX2014010701A (es) 2015-03-10
DOP2014000200A (es) 2014-10-15
US9334267B2 (en) 2016-05-10
NZ627454A (en) 2016-09-30
EA201491456A1 (ru) 2014-12-30
CA2863673A1 (en) 2013-09-12
JP2015509536A (ja) 2015-03-30
WO2013134252A1 (en) 2013-09-12
BR112014018528A8 (pt) 2017-07-11
PT2850082T (pt) 2016-07-15
CR20140378A (es) 2014-11-27
DK2850082T3 (en) 2016-08-15
MA37316B1 (fr) 2017-03-31
EA024824B1 (ru) 2016-10-31
CL2014002220A1 (es) 2015-06-05
BR112014018528A2 (OSRAM) 2017-06-20
IN2014MN01575A (OSRAM) 2015-05-08
CO7010837A2 (es) 2014-07-31
TN2014000375A1 (en) 2015-12-21
ME02423B (me) 2016-09-20
LT2850082T (lt) 2016-09-12
US20130252977A1 (en) 2013-09-26
AU2013230146B2 (en) 2015-09-10
HK1202541A1 (en) 2015-10-02
HRP20160654T1 (hr) 2016-07-01
CN104302646B (zh) 2016-05-04
KR20140129087A (ko) 2014-11-06
RS54840B1 (sr) 2016-10-31
US8741911B2 (en) 2014-06-03
AR090151A1 (es) 2014-10-22
AU2013230146A1 (en) 2014-08-14
AP2014007899A0 (en) 2014-08-31
US20150119392A1 (en) 2015-04-30
ECSP14017584A (es) 2016-01-29
PH12014501986B1 (en) 2014-11-24
MA37316A1 (fr) 2016-06-30
CY1117846T1 (el) 2017-05-17
CN104302646A (zh) 2015-01-21
SG11201404969YA (en) 2014-10-30
EP2850082B1 (en) 2016-05-18
HUE028095T2 (en) 2016-11-28
EP2850082A1 (en) 2015-03-25
PH12014501986A1 (en) 2014-11-24
ES2584387T3 (es) 2016-09-27
TW201348233A (zh) 2013-12-01
WO2013134243A1 (en) 2013-09-12
SI2850082T1 (sl) 2016-07-29

Similar Documents

Publication Publication Date Title
PE20142338A1 (es) Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf
MY175450A (en) 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
JO3160B1 (ar) مشتقات الفوسفات الجديدة, طريقة تحضيرها والتركيبات الدوائية التي تحتوي عليها
PH12014501488A1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
JO3310B1 (ar) مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
PE20170146A1 (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
EA201600128A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2(1Н)-ОНА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ И АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
PH12015502118A1 (en) Pyridin-4-yl derivatives
MX2015007053A (es) Compuestos dimericos.
LT2864323T (lt) 1,3-dihidro-2h-benzimidazol-2-ono dariniai, turintys heterociklų pakaitų, kaip antivirusiniai agentai prieš respiratorinį sincitinį virusą
PH12015500716A1 (en) N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
PL3013774T3 (pl) Wodny preparat zawiesinowy i jego zastosowanie jako nawozu dolistnego
AR092772A1 (es) Derivado de 7-azaindol
IN2015DN03174A (OSRAM)
RU2013107122A (ru) 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
EA201400882A1 (ru) Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях
Guerra MBA Presentations July 2013 The following presentations will be held at the University Boardroom (Room 206). Monday, 7/22/2013
UA109405C2 (ru) 6-(2-r-метилселено)- 4-(2-метоксифенил)-2-оксо-1,2,3,4-тетрагидропиридин-3,5-дикарбонитрилы

Legal Events

Date Code Title Description
FD Application declared void or lapsed